MGIA
TBPH icon

Moneta Group Investment Advisors’s Theravance Biopharma TBPH Stock Holding History

Moneta Group Investment Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,442
Closed -$40K – 708
2017
Q4 		$40K Sell
1,442
-7,300
-84% -$216K 0.01% 283
2017
Q3 		$299K Buy
+8,742
New +$286K 0.05% 159

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Moneta Group Investment Advisors's TBPH Position: Q1 2018 in Review

Moneta Group Investment Advisors sold out of Theravance Biopharma (TBPH) in Q1 2018, closing a stake of 1,442 shares — an estimated $40K sold.

Moneta Group Investment Advisors first reported a position in TBPH in Q3 2017 and held it in 2 quarters. The position peaked at $299K in Q3 2017. 90 funds tracked by Wall St. Rank hold TBPH as of Q1 2018.

  • Moneta Group Investment Advisors reported no remaining Theravance Biopharma position as of Q1 2018 after selling out during the quarter.
  • Moneta Group Investment Advisors sold 1,442 Theravance Biopharma shares in Q1 2018, an estimated $40K.
  • Moneta Group Investment Advisors first reported a position in Theravance Biopharma in Q3 2017 and held it in 2 quarters.
  • Moneta Group Investment Advisors's Theravance Biopharma position peaked at $299K in Q3 2017.
  • 90 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2018.

Based on Moneta Group Investment Advisors's 13F filing for Q1 2018, filed 14 May 2018.